Glucosylceramide synthase blockade down-regulates P-glycoprotein and resensitizes multidrug-resistant breast cancer cells to anticancer drugs.
about
Roles of bioactive sphingolipids in cancer biology and therapeuticsA review of ceramide analogs as potential anticancer agentsBiophysics of cell membrane lipids in cancer drug resistance: Implications for drug transport and drug delivery with nanoparticlesA new mixed-backbone oligonucleotide against glucosylceramide synthase sensitizes multidrug-resistant tumors to apoptosisRe-configuration of sphingolipid metabolism by oncogenic transformation.Recent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapiesCeramide glycosylation catalyzed by glucosylceramide synthase and cancer drug resistance.Direct assessment of P-glycoprotein efflux to determine tumor response to chemotherapy.Glucosylceramide synthase upregulates MDR1 expression in the regulation of cancer drug resistance through cSrc and beta-catenin signaling.Mixed backbone antisense glucosylceramide synthase oligonucleotide (MBO-asGCS) loaded solid lipid nanoparticles: in vitro characterization and reversal of multidrug resistance in NCI/ADR-RES cellsGaucher's disease and cancer: a sphingolipid perspectiveInterdiction of sphingolipid metabolism to improve standard cancer therapies.Apoptotic sphingolipid ceramide in cancer therapy.P-glycoprotein antagonists confer synergistic sensitivity to short-chain ceramide in human multidrug-resistant cancer cells.Multi-modal strategies for overcoming tumor drug resistance: hypoxia, the Warburg effect, stem cells, and multifunctional nanotechnology.4-IBP, a sigma1 receptor agonist, decreases the migration of human cancer cells, including glioblastoma cells, in vitro and sensitizes them in vitro and in vivo to cytotoxic insults of proapoptotic and proautophagic drugsDoxorubicin and MBO-asGCS oligonucleotide loaded lipid nanoparticles overcome multidrug resistance in adriamycin resistant ovarian cancer cells (NCI/ADR-RES).Lipidomic approach for stratification of acute myeloid leukemia patients.Novel analogs of D-e-MAPP and B13. Part 2: signature effects on bioactive sphingolipids.Novel analogs of D-e-MAPP and B13. Part 1: synthesis and evaluation as potential anticancer agents.Sphingolipids in cancer: regulation of pathogenesis and therapy.Ceramide and glucosylceramide upregulate expression of the multidrug resistance gene MDR1 in cancer cellsCeramide signaling in cancer and stem cells.Multi-functional nanocarriers to overcome tumor drug resistanceAltered methylation of glucosylceramide synthase promoter regulates its expression and associates with acquired multidrug resistance in invasive ductal breast cancer.RNAi-mediated functional analysis of pathways influencing cancer cell drug resistance.Sphingolipids as determinants of apoptosis and chemoresistance in the MCF-7 cell model system.Glycosphingolipid storage in Fabry mice extends beyond globotriaosylceramide and is affected by ABCB1 depletion.Inhibition of glucosylceramide synthase eliminates the oncogenic function of p53 R273H mutant in the epithelial-mesenchymal transition and induced pluripotency of colon cancer cells.Expression of glucosylceramide synthase in invasive ductal breast cancer may be correlated with high estrogen receptor status and low HER-2 statusSphingolipids and cancer: ceramide and sphingosine-1-phosphate in the regulation of cell death and drug resistance.Fexofenadine hydrochloride in the treatment of allergic disease: a reviewImplication of ceramide, ceramide 1-phosphate and sphingosine 1-phosphate in tumorigenesis.Therapeutic potential of targeting ceramide/glucosylceramide pathway in cancer.Glucosylceramide synthase inhibitors differentially affect expression of glycosphingolipids.Molecular mechanisms of drug resistance and its reversal in cancer.3-Ketone-4,6-diene ceramide analogs exclusively induce apoptosis in chemo-resistant cancer cells.Delivery systems of ceramide in targeted cancer therapy: ceramide alone or in combination with other anti-tumor agents.Glucosylceramide synthase promotes Bcl-2 expression via the ERK signaling pathway in the K562/A02 leukemia drug-resistant cell line.Tackling breast cancer chemoresistance with nano-formulated siRNA.
P2860
Q24657499-01C904E1-FC25-4FB5-8BA5-B97A22191704Q27009351-8F1F8175-8292-442B-979A-FC586A176626Q27026080-C818666C-08AA-4264-8263-D2044ABCBD48Q28476087-602AAA75-64FC-49B5-8928-EE09F790E840Q33649823-AD1AD986-3EBF-4F47-B830-5A1E141406C8Q33730375-4D6EF6E5-7627-4D13-8C5B-44A99813FC16Q33733991-17038F6F-411F-4671-84F4-1916F58A14B6Q33814552-CA01103E-D949-4A8B-9CCA-3A57B6E4F13FQ33991690-181BFB6B-0604-4F5F-B2AA-DF47DAB850D1Q34188396-34B4B066-360D-4276-8545-7DACDE8BFF47Q34333982-B09FDE77-E63D-4D57-A7BB-F232876700B8Q34373466-A169BD52-C250-429A-A0E2-54132C6BC00BQ34736760-4036A04F-A128-4805-AB04-9D0DC3E98DECQ35057879-746BC89B-15E3-4278-A8BD-A57A90C46460Q35136562-CAAAA14D-F787-4A1C-95FB-565FF1577885Q35812711-DA23B576-1AE5-4DA3-9276-91BAF002999DQ35982475-2EF36F31-8FB6-409D-8321-E40DB90AA952Q36282427-CE136153-75D1-4A76-BF85-094F16D53B16Q36498966-6E70B781-A130-431C-944B-B2BBFD78AFA8Q36526990-A0243409-A35F-462C-82C1-0F70D76BC350Q36592826-1515BE29-C096-4C0F-AA9F-EC95D0C8DD8AQ36600615-6D9B2382-F768-4324-9A2A-21892722C3CBQ36803735-480956DC-2052-4427-8176-32EBCD5D8953Q36980340-10BE3C98-8C57-448C-805D-F1DE1FCAFB11Q37392829-9FCB05A9-3E11-4287-A46E-97BB0EC826C9Q37494793-36468FE3-8479-4134-89A4-659BC7E34D8CQ37527497-CD1F1141-8D80-49BF-81B6-1EA9687A2FC8Q37591813-48B81831-7D1F-4662-BD5D-C6DE0A2D5E51Q37645066-A52473E8-CEBB-410B-8E7B-67A7117AE2CBQ37685348-0B2B408E-372F-489E-A0EB-5205C1D92374Q37808219-27EF553B-5800-4858-A1C4-BAB12A9B5ADDQ37857671-B05D6D22-41B2-4658-BDA1-F599CAD54E8DQ37874939-0B5E60D8-9135-4B78-BDED-C42D6B85B2C4Q38052818-786B6C20-D6E0-44F7-B466-D34ABEDDEC04Q38365196-0E216BC3-14AC-426B-A1A9-D8D2C896727BQ38372575-7AFBC1BB-5759-4643-A777-425D5F04B689Q38539202-F697D336-AF00-445E-96A3-A5082412CEE3Q38831997-D06D09B5-E5B7-4446-A1EF-E125F4282F4AQ38950710-FA8BAC68-F876-4252-8430-1859ADE52759Q38959517-5C040FDB-8A3F-482A-948B-FFA98B1CADF4
P2860
Glucosylceramide synthase blockade down-regulates P-glycoprotein and resensitizes multidrug-resistant breast cancer cells to anticancer drugs.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Glucosylceramide synthase bloc ...... cer cells to anticancer drugs.
@en
type
label
Glucosylceramide synthase bloc ...... cer cells to anticancer drugs.
@en
prefLabel
Glucosylceramide synthase bloc ...... cer cells to anticancer drugs.
@en
P2093
P1433
P1476
Glucosylceramide synthase bloc ...... cer cells to anticancer drugs.
@en
P2093
Armando E Giuliano
Carlton S Prickett
Myles C Cabot
Valérie Gouazé
P304
P356
10.1158/0008-5472.CAN-04-2329
P407
P50
P577
2005-05-01T00:00:00Z